Quality-of-Life Effects of Prophylactic Salpingo-Oophorectomy Versus Gynecologic Screening Among Women at Increased Risk of Hereditary Ovarian Cancer
Authors:
- Judith HollensteinJHJudith Hollenstein
- Eveline BleikerEBEveline Bleiker
- Marc van BeurdenMBMarc van Beurden
- Heiddis B. ValdimarsdottirHVHeiddis B. Valdimarsdottir
- Leon F. MassugerLMLeon F. Massuger
- Katja N. GaarenstroomKGKatja N. Gaarenstroom
- Marian J.E. MouritsMMMarian J.E. Mourits
- René H.M. VerheijenRVRené H.M. Verheijen
- Eleonora B.L. van DorstEDEleonora B.L. van Dorst
- Hans van der PuttenHPHans van der Putten
- Ko van der VeldenKVKo van der Velden
- 1 October 2005
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (28) , 6890-6898
Abstract
Purpose Recommendations for women at high risk of ovarian cancer include periodic gynecologic screening (GS) and prophylactic bilateral salpingo-oophorectomy (PBSO). The aim of the current study was to determine the quality-of-life (QOL) effects of PBSO versus GS. Patients and Methods Questionnaire data were obtained from 846 high-risk women who had participated in this nationwide, cross-sectional, observational study. Forty-four percent of the women had undergone PBSO, and 56% had opted for GS. Topics addressed by the questionnaire included generic QOL, cancer-specific distress, endocrine symptoms, and sexual functioning. Results No statistically significant between-group differences were observed in generic QOL (Short Form-36), with women in both the PBSO and GS groups scoring similarly to the general population. Compared with GS, PBSO was associated with fewer breast and ovarian cancer worries (P < .001) and more favorable cancer risk perception (P < .05). However, the PBSO group reported significantly more endocrine symptoms (P < .001) and worse sexual functioning (P < .05) than the GS group. Eighty-six percent of women would choose PBSO again, and 63% would recommend it to a friend with familial risk of ovarian cancer. Conclusion PBSO had no measurable adverse impact on generic QOL of high-risk women. The favorable effects of PBSO in terms of reduced cancer worries and low perceived cancer risk need to be weighed against the increase in endocrine and sexual symptoms. Balanced information will help clinicians and high-risk women to make informed decisions about the optimal preventive health strategy.Keywords
This publication has 30 references indexed in Scilit:
- Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2Science, 2003
- Ovarian cancer and high-risk women—implications for prevention, screening, and early detectionGynecologic Oncology, 2003
- Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 StudiesThe American Journal of Human Genetics, 2003
- Risk-Reducing Salpingo-oophorectomy in Women with aBRCA1orBRCA2MutationNew England Journal of Medicine, 2002
- Prophylactic Oophorectomy in Carriers ofBRCA1orBRCA2MutationsNew England Journal of Medicine, 2002
- Screening for ovarian cancer: a pilot randomised controlled trialThe Lancet, 1999
- Vasomotor flushes in menopausal womenAmerican Journal of Obstetrics and Gynecology, 1999
- The performance of screening tests for ovarian cancer: results of a systematic reviewBJOG: An International Journal of Obstetrics & Gynaecology, 1998
- The genetic attributable risk of breast and ovarian cancerCancer, 1996
- Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the gilda radner familial ovarian cancer registryCancer, 1993